Advanced glycation end-products (AGEs) constitute a non-homogenous, chemically diverse
group of compounds formed either exogeneously or endogeneously on the course of …

Blood vessel endothelial cells (ECs) have long been known to modulate inflammation by
regulating immune cell trafficking, activation status and function. However, whether the …

Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

The stealth effect plays a central role on capacitating nanomaterials for drug delivery
applications through improving the pharmacokinetics such as blood circulation …

Chronic liver injury leads to liver inflammation and fibrosis, through which activated
myofibroblasts in the liver secrete extracellular matrix proteins that generate the fibrous scar …

The heterogeneity of endothelial cells (ECs) across tissues remains incompletely
inventoried. We constructed an atlas of> 32,000 single-EC transcriptomes from 11 mouse …

Liver sinusoidal endothelial cells (LSECs) form the wall of the hepatic sinusoids. Unlike
other capillaries, they lack an organized basement membrane and have cytoplasm that is …

Lipid nanoparticles (LNPs) are the leading nonviral technologies for the delivery of
exogenous RNA to target cells in vivo. As systemic delivery platforms, these technologies …

Hepatocellular carcinoma (HCC) is the most common liver tumor and among the deadliest
cancers worldwide. Advanced HCC overall survival is meager and has not improved over …